Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).

被引：3

作者：

Dougherty, Brian

Ledermann, Jonathan A.

Lai, Zhongwu

Robertson, Jane D.

Ho, Tony

Hodgson, Darren R.

O'Connor, Mark J.

Fielding, Anitra

Hawryluk, Matthew J.

Brennan, Tim

Yelensky, Roman

Sun, James

Barrett, J. Carl

机构：

[1] AstraZeneca, Waltham, MA USA

[2] UCL, Inst Canc, London, England

[3] AstraZeneca, Macclesfield, Cheshire, England

[4] AstraZeneca, Wilmington, DE USA

[5] Fdn Med Inc, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.5536

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5536

引用

页数：1

共 50 条

[21] Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
Liu, Ying L.
Mathews, Cara A.
Simpkins, Fiona
Cadoo, Karen A.
Provencher, Diane
Mccormick, Colleen C.
Elnaggar, Adam C.
Altman, Alon D.
Gilbert, Lucy
Black, Destin
Kabil, Nashwa
Taylor, Rosie N.
Barnicle, Alan
Munley, Jiefen Y.
Aghajanian, Carol
CANCER, 2025, 131 (02)
[22] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
Penson, R. T.
Valencia, R. V.
Cibula, D.
Colombo, N.
Ill, C. L.
Bidzinski, M.
Kim, J. W.
Nam, J. H.
Madry, R.
Hernandez, C. H.
Mora, P.
Ryu, S. Y.
Milenkova, T.
Lowe, E.
Barker, L.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
[23] Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial EDITORIAL COMMENT
Ledermann, Jonathan
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Spencer, Stuart
Dougherty, Brian
Orr, Maria
Hodgson, Darren
Barrett, J. Carl
Matulonis, Ursula
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2014, 69 (10) : 594 - 596
[24] Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
Mathews, Cara Amanda
Simpkins, Fiona
Cadoo, Karen Anne
Liu, Ying L.
Provencher, Diane M.
McCormick, Colleen
ElNaggar, Adam
Altman, Alon D.
Gilbert, Lucy
Black, Destin
Kabil, Nashwa
Bennett, James
Munley, Jiefen
Yu, Judy
Aghajanian, Carol
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
Gao, Qinglei
Zhu, Jianqing
Zhao, Weidong
Huang, Yi
An, Ruifang
Zheng, Hong
Qu, Pengpeng
Wang, Li
Zhou, Qi
Wang, Danbo
Lou, Ge
Wang, Jing
Wang, Ke
Low, John
Kong, Beihua
Rozita, Abdul Malik
Sen, Lim Chun
Yin, Rutie
Xie, Xing
Liu, Jihong
Sun, Wei
Su, Jingya
Zhang, Chunyi
Zang, Rongyu
Ma, Ding
CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2278 - 2285
[26] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Penson, Richard T.
Valencia, Ricardo Villalobos
Cibula, David
Colombo, Nicoletta
Leath, Charles A.
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo-Hyun
Madry, Radoslaw
Hernandez, Carlos Hernandez
Mora, Paulo Alexandre Ribeiro
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
Friedlander, M.
Gebski, V.
Gibbs, E.
Bloomfield, R.
Hilpert, F.
Wenzel, L. B.
Joly, F.
Eek, D.
Rodrigues, M.
Clamp, A.
Penson, R.
Provencher, D.
Korach, J.
Huzarski, T.
Vidal, L.
Salutari, V.
Scott, C.
Nicoletto, M. O.
Tamura, K.
Pujade-Lauraine, E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941
[28] Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the phase II LIGHT study
Cadoo, Karen
Simpkins, Fiona
Mathews, Cara
Altman, Alon
Gilbert, Lucy
Liu, Ying
Black, Destin
Munley, Jiefen
Kabil, Nashwa
Bennett, James
Yu, Hong
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2021, 162 : S67 - S68
[29] Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary efficacy results from the phase II LIGHT study
Cadoo, Karen
Simpkins, Fiona
Mathews, Cara
Liu, Ying
Provencher, Diane
McCormick, Colleen
ElNaggar, Adam
Kabil, Nashwa
Bennett, James
Yu, Hong
Munley, Jiefen
Aghajanian, Carol
GYNECOLOGIC ONCOLOGY, 2021, 162 : S217 - S217
[30] Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
Ryota Tashiro
Hitoshi Kawazoe
Kanako Mamishin
Keisuke Seto
Ryoko Udagawa
Yoshimasa Saito
Hironobu Hashimoto
Tatsunori Shimoi
Kan Yonemori
Masahito Yonemura
Hiroyuki Terakado
Takahiro Nishimura
Toshikatsu Kawasaki
Tetsuya Furukawa
Tomonori Nakamura
Scientific Reports, 13

← 1 2 3 4 5 →